4.4 Review

Inclusionary Trials: A Review of Lessons Not Learned

Journal

EPIDEMIOLOGIC REVIEWS
Volume 44, Issue 1, Pages 78-86

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/epirev/mxac007

Keywords

clinical trials; community-based; inclusion; inclusive participation; minority recruitment; vaccine trials

Funding

  1. National Heart, Lung, and Blood Institute Community Engagement [Alliance/STOP COVID-19, CA 21-312-0217571-66106L]
  2. National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR003142]
  3. Michael J. Fox Foundation for Parkinson's Research [MJFF-019595]

Ask authors/readers for more resources

The COVID-19 pandemic has exposed weaknesses in the US public health infrastructure, particularly in engaging marginalized communities in clinical research. Inclusive participation is crucial for promoting vaccine confidence and trust in addressing health disparities. The concept of community-based participatory research, which involves community members in all research phases, can help increase participation and trust. However, there is currently a lack of community partnership in epidemiologic and clinical research, which takes time to develop. We outline practices to improve inclusion and suggest steps for trialists and researchers to increase marginalized communities' participation.
The COVID-19 pandemic revealed weaknesses in the public health infrastructure of the United States, including persistent barriers to engaging marginalized communities toward inclusion in clinical research, including trials. Inclusive participation in clinical trials is crucial for promoting vaccine confidence, public trust, and addressing disparate health outcomes. A long-standing body of literature describes the value of community-based participatory research in increasing marginalized community participation in research. Community-based participatory research emphasizes shared leadership with community members in all phases of the research process, including in the planning and implementation, interpretation, and dissemination. Shared leadership between academic and industry with marginalized communities can assist with inclusive participation in vaccine trials and increase public trust in the development of the vaccines and other therapies used during public emergencies. Nevertheless, epidemiologic and clinical research do not yet have a strong culture of community partnership in the scientific process, which takes time to build and therefore may be difficult to develop and rapidly scale to respond to the pandemic. We outline practices that contribute to a lack of inclusive participation and suggest steps that trialists and other researchers can take to increase marginalized communities' participation in research. Practices include planning for community engagement during the planning and recruitment phases, having regular dialogues with communities about their priorities, supporting them throughout a study, and navigating complex structural determinants of health. Additionally, we discuss how research institutions can support inclusive practices by reexamining their policies to increase participation in clinical trials and instilling institutional trustworthiness.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available